FDA generic-drugs chief resigns

03/14/2013 | Pharmalot.com

Dr. Greg Geba announced he will resign as director of the FDA's Office of Generic Drugs, just as the FDA has started collecting generic-drug manufacturer user fees. A planned reorganization of the office played a role in his decision, Geba said in a memo. Dr. Janet Woodcock, director of the Center for Drug Evaluation & Research, will temporarily cover Geba's duties.

View Full Article in:

Pharmalot.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Counsel, Regulatory (FDA)
CareFusion
San Diego , CA
Health Care Exchange Account Manager
Kaiser Permanente
San Diego, CA
Director, Health Plan Operations
Group Health Cooperative
Seattle, WA
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations